SET/TAF-I Antikörper (N-Term)

Produktnummer ABIN374103

Produktdetails anti-SET/TAF-I Antikörper

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Bindungsspezifität: N-Term

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser SET/TAF-I Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Sequenz: SAPAAKVSKK ELNS-C

Spezifität: This antibody detects SET / I2PP2A at N-term.

Kreuzreaktivität (Details): Species reactivity (expected):Bovine (Cow)Species reactivity (tested):Human.

Aufreinigung: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogen: Peptide from the N Terminus of the protein sequence according to NP_003002.2

Anwendungsinformationen

Applikationshinweise: Peptide ELISA: Limit Dilution 1/1000. Western blot: 1-3 μg/mL. Approx 20-25 kDa and 45 kDa bands seen in Human Kidney

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu SET/TAF-I

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Andere Bezeichnung: SET / I2PP2A (SET Produkte)

Synonyme: 2PP2A antikoerper, I2PP2A antikoerper, IGAAD antikoerper, IPP2A2 antikoerper, PHAPII antikoerper, TAF-I antikoerper, TAF-IBETA antikoerper, 2610030F17Rik antikoerper, 5730420M11Rik antikoerper, AA407739 antikoerper, I-2PP2A antikoerper, StF-IT-1 antikoerper, 2pp2a antikoerper, i2pp2a antikoerper, igaad antikoerper, ipp2a2 antikoerper, phapii antikoerper, set antikoerper, set-a antikoerper, set-b antikoerper, taf-ibeta antikoerper, wu:fb30g11 antikoerper, wu:fd16c08 antikoerper, SET nuclear proto-oncogene antikoerper, SET nuclear oncogene antikoerper, SET translocation antikoerper, SET nuclear proto-oncogene L homeolog antikoerper, SET nuclear proto-oncogene b antikoerper, SET antikoerper, Set antikoerper, LOC403555 antikoerper, set.L antikoerper, setb antikoerper

Hintergrund: SET belongs to a family of multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. There are two named isoforms produced by alternative splicing: Isoform 1 and Isoform 2. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher. Isoform 1 and isoform 2 interact directly with each other and with ANP32A within the tripartite INHAT (inhibitor of acetyltransferases) complex. A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6,9)(q21,q34.1) with NUP214/CAN.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

Gen-ID: 6418

NCBI Accession: NP_003002

UniProt: H0UI37

Pathways: Apoptose